A recombinant bivalent human papillomavirus vaccine was approved Oct. 16 for the prevention of cervical cancer and certain precancerous or dysplastic lesions caused by HPV types 16 and 18 in girls and women aged 10-25 years. The Food and Drug Administration followed the advice of its Vaccines and Related Biological Products Advisory Committee, which found that data supported the efficacy of the vaccine for preventing HPV 16/18-related cervical cancer, cervical intraepithelial neoplasia (CIN) 2+,...